BMY — Bristol-Myers Squibb Co Share News
0.000.00%
Last trade - 00:00- $110.27bn
- $144.28bn
- $48.19bn
Brief: Hengrui Pharma And Bristol Myers Squibb Announce Strategic Agreements To Advance Innovative Medicines
Brief: Jiangsu Hengrui Pharmaceuticals Enters Collaboration And License Deals With Bristol-Myers Squibb
China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
Bayer's experimental blood thinner cuts risk and severity of repeat strokes (updated)
Cytokinetics jumps as heart disease drug meets goals in late-stage trial
Cytokinetics jumps as heart disease drug meets goals in late-stage trial
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales (updated)
Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
Media: Mark Cuban’s online pharmacy to sell blockbuster blood thinner Eliquis- Bloomberg News
Atrium Therapeutics rises on $15 million milestone payment from Bristol Myers Squibb
Replimune tumbles after FDA declines to approve melanoma drug
US FDA declines to approve Replimune's drug for advanced skin cancer (updated)
US FDA declines to approve Replimune's drug for advanced skin cancer
Brief: Boehringer Ingelheim To Evaluate Combination Of Dll3‑Targeting T‑Cell Engager Plus Pd‑L1/Vegf‑A Bispecific Antibody In Small Cell Lung Cancer
Brief: Oxford Biotherapeutics Trategic Collaboration With Bristol Myers Squibb To Discover And Develop Next-Generation T-Cell Engagers For Solid Tumours
Needham initiates coverage of MapLight on schizophrenia drug potential